X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs ASTRAZENECA PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA ASTRAZENECA PHARMA DISHMAN PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 25.1 102.7 24.4% View Chart
P/BV x 3.3 28.6 11.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
ASTRAZENECA PHARMA
Mar-14
DISHMAN PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,285 29.1%   
Low Rs129634 20.3%   
Sales per share (Unadj.) Rs197.8189.6 104.3%  
Earnings per share (Unadj.) Rs21.2-0.2 -10,415.4%  
Cash flow per share (Unadj.) Rs34.73.8 903.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.968.6 262.1%  
Shares outstanding (eoy) m80.6925.00 322.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.35.1 25.1%   
Avg P/E ratio x11.9-4,712.7 -0.3%  
P/CF ratio (eoy) x7.2249.6 2.9%  
Price / Book Value ratio x1.414.0 10.0%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,30623,988 84.7%   
No. of employees `0000.81.6 53.2%   
Total wages/salary Rs m5,3551,605 333.7%   
Avg. sales/employee Rs Th19,252.73,040.2 633.3%   
Avg. wages/employee Rs Th6,459.51,029.2 627.6%   
Avg. net profit/employee Rs Th2,064.1-3.3 -63,219.2%   
INCOME DATA
Net Sales Rs m15,9614,740 336.7%  
Other income Rs m26592 288.2%   
Total revenues Rs m16,2264,832 335.8%   
Gross profit Rs m4,103-130 -3,161.2%  
Depreciation Rs m1,091101 1,077.7%   
Interest Rs m9440-   
Profit before tax Rs m2,334-139 -1,680.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m6245 12,251.5%   
Profit after tax Rs m1,711-5 -33,616.9%  
Gross profit margin %25.7-2.7 -938.8%  
Effective tax rate %26.7-3.7 -729.2%   
Net profit margin %10.7-0.1 -9,983.0%  
BALANCE SHEET DATA
Current assets Rs m11,0182,726 404.1%   
Current liabilities Rs m9,5172,435 390.8%   
Net working cap to sales %9.46.1 153.0%  
Current ratio x1.21.1 103.4%  
Inventory Days Days11074 149.8%  
Debtors Days Days3541 85.5%  
Net fixed assets Rs m16,3041,035 1,574.8%   
Share capital Rs m16150 322.8%   
"Free" reserves Rs m12,907942 1,369.6%   
Net worth Rs m14,5161,716 845.9%   
Long term debt Rs m4,1890-   
Total assets Rs m29,8054,156 717.2%  
Interest coverage x3.5NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.51.1 47.0%   
Return on assets %8.9-0.1 -7,274.7%  
Return on equity %11.8-0.3 -3,974.1%  
Return on capital %17.50-  
Exports to sales %24.85.7 434.8%   
Imports to sales %3.76.5 57.8%   
Exports (fob) Rs m3,956270 1,464.2%   
Imports (cif) Rs m596306 194.7%   
Fx inflow Rs m4,952375 1,321.8%   
Fx outflow Rs m697470 148.2%   
Net fx Rs m4,255-96 -4,452.9%   
CASH FLOW
From Operations Rs m2,786-8 -34,400.0%  
From Investments Rs m-1,529-146 1,049.3%  
From Financial Activity Rs m-941862 -109.2%  
Net Cashflow Rs m316709 44.7%  

Share Holding

Indian Promoters % 61.4 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.7 0.3 1,233.3%  
FIIs % 12.7 15.7 80.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 9.1 242.9%  
Shareholders   46,261 12,856 359.8%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   J.B.CHEMICALS  SUVEN LIFESCIENCES  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Higher, Oil Prices, and Top Cues in Focus Today(Pre-Open)

Indian share markets witnessed volatility during closing hours yesterday and ended their day marginally higher.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

Sensex Nearing All-Time Highs: Stocks to Buy in this Rally(Profit Hunter)

Mar 14, 2019

The BSE Sensex is heating up. In just a few days, the benchmark index is up 3%. Is this rally sustainable? Richa finds out...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS